Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bianca Posocco

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Plos One|November 20, 2019
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patientsValentina Iacuzzi, Bianca Posocco, Martina Zanchetta, et al.
International Journal of Molecular Sciences|February 25, 2023
Impact of <i>ABCG2</i> and <i>ABCB1</i> Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-AnalysisChiara Dalle Fratte, Jerry Polesel, Sara Gagno, et al.
Plos One|February 8, 2020
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical applicationBianca Posocco, Mauro Buzzo, Ariana Soledad Poetto, et al.
Plos One|October 26, 2021
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoringMartina Zanchetta, Valentina Iacuzzi, Bianca Posocco, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 21, 2023
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancerElena Peruzzi, Lorenzo Gerratana, Marcella Montico, et al.
Frontiers in Pharmacology|August 9, 2022
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast CancerRossana Roncato, Lorenzo Gerratana, Lorenza Palmero, et al.
British Journal of Clinical Pharmacology|September 30, 2022
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patientsChiara Dalle Fratte, Sara Gagno, Rossana Roncato, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 26, 2021
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancerAriana Soledad Poetto, Bianca Posocco, Sara Gagno, et al.
International Journal of Molecular Sciences|April 14, 2026
LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer PatientsBianca Posocco, Diletta Pasin, Nicoletta De Cesaro, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 9, 2023
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposureRossana Roncato, Elena Peruzzi, Lorenzo Gerratana, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Plos One|November 20, 2019
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patientsValentina Iacuzzi, Bianca Posocco, Martina Zanchetta, et al.
International Journal of Molecular Sciences|February 25, 2023
Impact of <i>ABCG2</i> and <i>ABCB1</i> Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-AnalysisChiara Dalle Fratte, Jerry Polesel, Sara Gagno, et al.
Plos One|February 8, 2020
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical applicationBianca Posocco, Mauro Buzzo, Ariana Soledad Poetto, et al.
Plos One|October 26, 2021
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoringMartina Zanchetta, Valentina Iacuzzi, Bianca Posocco, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 21, 2023
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancerElena Peruzzi, Lorenzo Gerratana, Marcella Montico, et al.
Frontiers in Pharmacology|August 9, 2022
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast CancerRossana Roncato, Lorenzo Gerratana, Lorenza Palmero, et al.
British Journal of Clinical Pharmacology|September 30, 2022
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patientsChiara Dalle Fratte, Sara Gagno, Rossana Roncato, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 26, 2021
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancerAriana Soledad Poetto, Bianca Posocco, Sara Gagno, et al.
International Journal of Molecular Sciences|April 14, 2026
LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer PatientsBianca Posocco, Diletta Pasin, Nicoletta De Cesaro, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 9, 2023
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposureRossana Roncato, Elena Peruzzi, Lorenzo Gerratana, et al.
Pageof 5